Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cancer Research Technology Program, Antibody Characterization Lab, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Sci Data. 2019 Aug 29;6(1):160. doi: 10.1038/s41597-019-0166-7.
RAS genes are frequently mutated in cancer and have for decades eluded effective therapeutic attack. The National Cancer Institute's RAS Initiative has a focus on understanding pathways and discovering therapies for RAS-driven cancers. Part of these efforts is the generation of novel reagents to enable the quantification of RAS network proteins. Here we present a dataset describing the development, validation (following consensus principles developed by the broader research community), and distribution of 104 monoclonal antibodies (mAbs) enabling detection of 27 phosphopeptides and 69 unmodified peptides from 20 proteins in the RAS network. The dataset characterizes the utility of the antibodies in a variety of applications, including Western blotting, immunoprecipitation, protein array, immunohistochemistry, and targeted mass spectrometry. All antibodies and characterization data are publicly available through the CPTAC Antibody Portal, Panorama Public Repository, and/or PRIDE databases. These reagents will aid researchers in discerning pathways and measuring expression changes in the RAS signaling network.
RAS 基因在癌症中经常发生突变,几十年来一直难以进行有效的治疗性攻击。美国国立癌症研究所的 RAS 计划专注于了解途径和发现针对 RAS 驱动的癌症的治疗方法。这些努力的一部分是生成新的试剂,以实现对 RAS 网络蛋白的定量。在这里,我们提供了一个数据集,描述了开发、验证(遵循更广泛的研究界制定的共识原则)和分布的 104 种单克隆抗体 (mAb),这些抗体能够检测 RAS 网络中 20 种蛋白质的 27 个磷酸肽和 69 个未修饰肽。该数据集描述了这些抗体在各种应用中的效用,包括 Western blot、免疫沉淀、蛋白质阵列、免疫组织化学和靶向质谱。所有的抗体和特征化数据都可以通过 CPTAC 抗体门户、Panorama 公共存储库和/或 PRIDE 数据库获得。这些试剂将帮助研究人员辨别 RAS 信号网络中的途径和测量表达变化。